Trial Profile
Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex) in Patients at High Risk of Carrying Blood Diseases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Antithymocyte globulin; Fludarabine
- Indications Haematological malignancies
- Focus Therapeutic Use
- 10 Dec 2019 Results evaluating two conditioning groups: BxPK: n=27; PK-guided busulfan conditioning regimen from NCT02483325 study and BxPK: n=56; a retrospectively enrolled control cohort of patients with same inclusion criteria, assessing wheteher pharmacokinetics guided strategy improve the safety of busulfan were presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 22 Jan 2019 Status changed from recruiting to completed.
- 07 Jul 2015 New trial record